Clinical Trials Logo

Filter by:
NCT ID: NCT02864251 Completed - Clinical trials for Non-Small-Cell Lung Carcinoma

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

CheckMate722
Start date: March 17, 2017
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR TKI therapy.

NCT ID: NCT02864199 Completed - Clinical trials for Hepatitis C, Chronic

A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

Start date: February 2004
Phase: Phase 4
Study type: Interventional

This study will evaluate the pharmacokinetics (area under the curve [AUC], maximum concentration [Cmax], and other parameters) and tolerability of peginterferon alfa-2a and ribavirin combination therapy following single and multiple doses in participants with CHC infection and moderate to severe renal impairment or end-stage renal disease (ESRD) receiving hemodialysis. The anticipated time on study treatment is up to 48 weeks, and the target sample size is 48 individuals.

NCT ID: NCT02864121 Completed - Abnormal Cytology Clinical Trials

Oncogenous HPV DNA Integration (Intégration De l'ADN Des HPV Oncogènes)

IDAHO
Start date: December 2015
Phase: N/A
Study type: Interventional

High-risk human papillomavirus (HR-HPV) are involved in cervical cancer development. Integration of HR-HPV DNA in cellular genomes is considered as a major event in the cervical cancer development. The aim of this study is to validate the integration of the HPV-HR as an appropriate biomarker of the severity of precancerous lesions and progression of cervical lesions towards cervical cancer. HR-HPV integration status will be analyzed by Molecular Combing technology, which allows direct and high-resolution visualization of the integration of high-risk HPV genomes.

NCT ID: NCT02864017 Completed - Intubation Clinical Trials

Immuno Nutrition by L-citrulline for Critically Ill Patients

Immunocitre
Start date: September 2016
Phase: N/A
Study type: Interventional

The main objective of this study is to demonstrate that the only administration of L-citrulline, can improve immune functions in critically ill patients at high risk of nosocomial infection.

NCT ID: NCT02863627 Completed - Emergencies Clinical Trials

What Care Pathways for Newborns Consulting Pediatric Emergencies? Prospective Study Over One Year

NNUP
Start date: June 2016
Phase: N/A
Study type: Interventional

This study will evaluate the course of care of newborns, to understand why some newborns have improper care pathways, particularly as regards the first medical consultation at the exit of motherhood. It is also to organize a better quality care network to hospital discharge to avoid unnecessary use of pediatric emergencies, which represents a real public health problem.

NCT ID: NCT02862899 Completed - Clinical trials for Intraperitoneal Chemotherapy

Use of a Heating Cable to Obtain Hyperthermia During Intraperitoneal Chemotherapy

CHIPOFIL
Start date: January 2015
Phase: N/A
Study type: Interventional

The investigator will study the possibility of in situ heating of the liquid containing the chemotherapy, so as to avoid the need for an external pumping system with its complexity, and its associated risks and costs. The use of a heating cable (prototype hereinafter called Thermowire, made by the company EFS, which is in charge of its development) was patented and tested in pigs in two studies that included 15 animals altogether (in 7 of which the heating cable was used). The aim of the first study was the purely safety aspects, while the efficacy to obtain hyperthermia, the quality and the homogeneity of the hyperthermia and its effect on the tissue penetration of the chemotherapy were evaluated in a second study. The results obtained justify transfer to use in humans in the context of a clinical trial so as to obtain CE certification.

NCT ID: NCT02862886 Completed - Pregnancy Clinical Trials

Study of the Effect of Beta-3 Adrenergic Receptor Agonists on Oxidative Stress and Signalling Pathways Implicated in Remodelling of the Uteroplacental Space: Experimental in Vitro Approach on Myometrial Tissue Explants

STRESSOX
Start date: July 2010
Phase: N/A
Study type: Interventional

CHRONOLOGICAL DESCRIPTION OF THE STUDY 1. Information provided to study participants 2. Collection of written informed consent 3. Harvesting of myometrial biopsies 4. Creation of tissue explants using myometrial biopsies 5. Stimulation of the explants with LPS 6. Study of the effect of SAR150640 (beta3-adrenergic agonist) on LPS-induced oxidative stress Moreover, demonstrating the ability of beta3-adrenergic receptor agonists to prevent the appearance of oxidative stress and its consequences on tissues, as a complement to previous studies, is an additional argument for the clinical development of this class of pharmaceuticals in the management of threatened premature delivery and labour induction.

NCT ID: NCT02862860 Completed - Type-1 Diabetes Clinical Trials

Search for a Link Between the Different Variables for Glycaemia and Oxidative Stress or Impaired HDL Function

Holter Gly
Start date: May 29, 2012
Phase: N/A
Study type: Interventional

As glycaemic variability on the one hand and hypoglycaemia on the other are associated with oxidative stress and inflammation, they are likely, in type-1 diabetic patients, to affect the oxidation of lipoproteins and HDL function, by altering their anti-atherogenic properties. The aim of this study is thus to determine, in patients with Type 1 Diabetic (T1D) who will wear a glycaemic Holter for 1 week, the glycaemia parameters (mean glycaemia, duration of hypoglycaemia, duration of hyperglycaemia, mean amplitude of glycaemic excursions) associated with proatherogenic alterations in lipoproteins, in particular: - LDL oxidation - HDL oxidation and alterations of HDL function (anti-inflammatory capacity, antioxidant capacity)

NCT ID: NCT02862847 Completed - Gastro entérite Clinical Trials

Study of the Prevalence of Cosavirus and Salivirus Infections, Two New Genera of Picornaviridae, In Infants

COSALE
Start date: July 2015
Phase: N/A
Study type: Observational

Cosavirus and Salivirus are two new genera of Picornaviridae and are responsible for acute diarrhoea. They have been identified in the pathological stools of infants and immuno-compromised subjects on every continent with prevalences ranging from 2.8% to 8.8% depending on the virus, the cohort and the country studied. To date, no study on these two viruses has been conducted in France to evaluate the circulation and the pathogenicity of these viruses in subjects with diarrhoea. The aim of this study is thus to: - show that these viruses are in circulation in France in infants younger than 5 years old and that the proportions are similar to those reported in the literature. - confirm the relationship between the diarrhoea and the infection with these viruses.

NCT ID: NCT02862834 Completed - Poikiloderma Clinical Trials

Screening for Genes in Patients With Poikiloderma

poikiloderma
Start date: May 2013
Phase: N/A
Study type: Observational

In the context of this study, the investigators wish to take advantage of high-throughput genetic techniques (microarray and high-throughput exome sequencing) to identify new genes implicated in syndromic poikiloderma so as to improve the diagnostic decision tree in these syndromes, opportunities for genetic counselling for patients and their families and the follow-up of patients, notably with regard to the risk of tumours. This study will make it possible to identify new genes implicated in syndromic poikiloderma and improve the diagnostic strategy proposed to patients with these syndromes, and to propose to patients a confirmed diagnosis, appropriate follow-up, notably with regard to the risk of tumours, genetic counselling to families and eventually an antenatal diagnosis to couples who would like to have one for future pregnancies. The identification of new genetic causes of syndromic poikiloderma will also make it possible to complete the current classification of these syndromes